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Abstract
Introduction—Statins have been postulated to prevent infection through immunomodulatory
effects.
Objectives—To compare the incidence of infections in statin-users to that in non-users within
the same healthcare system.
Methods—This was a retrospective cohort study of patients enrolled as Tricare Prime or Plus in
the San Antonio military multi-market. Statin-users were patients who received a statin for at least
3 months between 10/1/2004 and 9/30/2005. Non-users were patients who did not receive a statin
within the study period (10/1/2003 to 9/30/2009). Inpatient and outpatient International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes were used to
Corresponding author and reprints: Ishak Mansi, MD, FACP, Internal Medicine Service, San Antonio Military Medical Center, 3551
Roger Brooke Drive, San Antonio, TX, 78234-6200, Office: (210) 916-0985, Fax: (210) 916-2077, Ishak.mansi@us.army.mil.
Conflict of interest:
CRF has received research grants and/or served as a scientific consultant/advisor for AstraZeneca, Bristol Myers Squibb, Elan, Forest,
Ortho-McNeil Janssen, and Pfizer.
Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army
Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army,
Department of Defense, Department of Veterans Affairs, or the U.S. Government.
NIH Public Access
Author Manuscript
Am J Med Sci. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:













determine the incidence of infections during the follow-up period (10/1/2005 to 9/30/2009) via
multivariable regression analysis and time to infection via Cox regression analysis.
Results—Of 45,247 patients who met the study criteria, 12,981 (29%) were statin-users and
32,266 were non-users. After adjustments for age, gender, Charlson Comorbidity Score, tobacco
use, alcohol abuse/dependence, health care utilization, and use of specific medication classes,
statin use was associated with an increased incidence of common infections [odds ratio (OR):
1.13; 95% CI: 1.06–1.19], but not influenza or fungal infections (OR: 1.06, 95% CI: 0.80–1.39;
OR: 0.97; 95% CI: 0.91–1.04, respectively). Time to first infection was similar in statin-users and
non-users in all infection categories examined.
Conclusion—Statin use was associated with an increased incidence of common infections, but
not influenza or fungal infections. This study does not support a protective role of statins in
infection prevention; however, the influence of potential confounders cannot be excluded.
Keywords
Statin; infection; fungal; influenza
Introduction
In addition to their beneficial effects on cardiovascular mortality and morbidity, hydroxyl
methyl glutaryl coenzyme A reductase inhibitors (statins) have been shown to have
pleotropic effects including reversing endothelial dysfunction,1, 2 decreasing inflammatory
cytokines,3, 4 and limiting sepsis-induced coagulopathy.5–7 These effects would potentially
be beneficial in patients with infection, hence, several studies have investigated the
association of statins and infection with mixed results. Some studies have found a beneficial
effect of statins on both infection prevention and improved outcomes, including
mortality.8–16 Other studies have found no significant effect,17–22 while still others found a
harmful effect.23 Several meta-analyses have also yielded conflicting results depending on
the included studies.24–26 Little is known of the relationship between statins and influenza or
fungal infections as most of these studies evaluated the effect of statins on bacterial
infections.
A major limitation of observational studies in relation to the effects of statins on infection is
that statin use may be a surrogate marker for a more “health-conscious patient” (healthy-user
bias) or receipt of care in a better health care system.27–29 The military health care system
offers similar accessibility and standards of care for all enrolled patients, thus, research
conducted in the military setting greatly reduces the likelihood of such a bias. The objective
of this study was to compare the incidence of infections in statin-users to that in non-users in
a setting of a more homogenous health care system.
Methods
This was a retrospective cohort study of patients in the San Antonio, TX Department of
Defense (DoD) multi-market between October 1, 2003 to September 30, 2009. This study
was approved by the Institutional Review Board at the Brooke Army Medical Center and the
University of Texas Health Science Center at San Antonio.
Medication fill and medical encounter diagnoses data were extracted using the Military
Health System Management Analysis and Reporting Tool (M2). These data encompass all
inpatient medical records, outpatient medical records, purchased care from facilities outside
military facilities, and medication fill records billed to the Military Health Care regardless of
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pharmacy location. The M2 is a reliable source of data, and has been successfully utilized in
previous research.30–32
The study period was divided into two main intervals. The baseline period encompassed the
dates October 1, 2003 to September 30, 2005 (fiscal years [FY] 2004–2005). This period
was used to describe patient baseline characteristics. Various comorbidities were determined
using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-
CM) codes during this period; the Charlson Comorbidity Score was then calculated using
the Deyo et al method.33 Outcomes were assessed during the follow-up period (FY 2006–
2009) using ICD-9-CM codes of interest (as defined below).
Patient groups
Patients were eligible for this study if they were 35 to 80 years of age, enrolled as Tricare
Prime or Plus to receive care at DoD medical facilities in the San Antonio area in 2009, had
at least one outpatient visit in the baseline period and one outpatient visit in the follow-up
period, and received at least one prescription medication in the baseline period. Therefore,
all our patients in the cohort were active in the Tricare system during the baseline period
(FY2004–2005) and in 2009. Patients were divided into two groups. Statin-users were
defined as patients who received any statin for at least three months between Oct 1, 2004
and Sep 30, 2005 (FY 2005). Statin non-users did not receive a statin within the study period
(FY 2004–2009).
Trauma and burn patients were excluded, since Brooke Army Medical Center (BAMC) is a
major burn and trauma center. Burn patients were identified based on ICD-9-CM codes
consistent with this diagnosis as compiled by the Agency for Health Research and Quality-
Clinical Classifications Software (AHRQ-CCS).34 Trauma codes were compiled from
ICD-9-CM manuals and previous publications.35, 36 Patients who were newly started on
statins after Sep 30, 2005 were excluded to allow for equal periods of follow-up between the
two comparison groups.
Outcome measures
The study outcomes included comparisons of the incidence and time-to-event of infectious
diseases groups in either the inpatient or outpatient setting between statin-users and non-
users:
• Common infections group: This group included a convenience sample of infections
commonly encountered in clinical practice and were defined using ICD-9-CM
codes. This group included acute respiratory infections (460–466),37–39 pneumonia
(480–483, 485–487), 40, 41 bacteremia (790.7), sepsis (995.91, 995.92,
996.64),42–44 skin infections (680–686),45–47 and urinary tract infections (590–
599).
• Influenza (487.x): This diagnosis was also included as a part of the common
infections group.
• Fungal infections: This group included dermatophytosis (110–111), candidiasis
(112), coccidioidomycosis (114), histoplasmosis (115), blastomycotic infection
(116), other mycoses (117), and opportunistic mycoses (118).
Statistical analysis
Continuous data were described as means ± standard deviations and dichotomous data were
described as percentages. Statin-users and non-users were compared with appropriate two-
way tests (i.e., Chi-square and Student’s t tests). Each infectious disease outcome was
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treated as a separate dependent variable and statin-use as an independent variable in
multivariable logistic regression analyses. Other covariates in the model were patient age,
gender, total Charlson Comorbidity Score (Deyo method33), tobacco use, alcohol
dependence/abuse, number of inpatient admissions in the baseline period, number of
outpatient visits in the baseline period, and use of the following medications: beta-blockers,
diuretics, calcium-channel blockers, ACE inhibitors, oral hypoglycemics, aspirin, and
steroids. The use of various classes of medications has been noted by some investigators to
characterize comorbidities,48 and some classes of medications have been noted to affect the
outcome of infections in conjunction with statins.49 Cox proportional hazards regression
analyses were used to compare time to infection. The same covariates were used in all
regression models. Results were presented as p-values, odds ratios, and 95% confidence
intervals. Comparisons were considered to be statistically significant if the calculated p-
value was less than an alpha level of 0.05. Data were analyzed using SAS 9.2 (SAS Institute,
Inc., Cary, NC) and JMP 8.0 (SAS Institute, Inc., Cary, NC).
Results
Of 56,028 patients that were identified, 45,247 patients met the study criteria; 10,781
patients were excluded (8,784 patients were newly started on statins after September 30,
2005, and 1,997 were burn or trauma patients). Of patients that met study criteria, 12,981
(29%) were statin-users and 32,266 were non-users. Among statin-users, the mean (standard
deviation) of cumulative duration of statin use was 1690 (666) days; 5.6% used statins for
less than 1 year, 12.1% for less than 2 years, and 20.5% for less than 3 years. Overall, 34.1%
used a maximum dose of statins defined as 80 mg of simvastatin, 80 mg of pravastatin, 80
mg of atorvastatin, or 40 mg of rosuvastatin. Baseline characteristics are presented in Table
1. In comparison to non-users, statin-users were significantly older (mean age 59.3 years vs.
44.4 years) and had a lower proportion of females (41.2% vs. 54.2%), a higher mean
Charlson Comorbidity Score (1.2 vs. 0.26), and greater health care utilization for both
inpatient and outpatient encounters. Additionally, statin-users had a higher rate of
medication utilization for most medication classes, excluding systemic corticosteroids.
Statin-users also had lower LDL and HDL levels compared to non-users.
During the follow-up period, the total number of patients who were diagnosed with an
infection consistent with the common infection diagnosis group among statin-users was
8,939 (68.9%) and non-users was 19,323 (59.9%). After adjustments for potential baseline
confounders, there was a significantly higher odds of having common infection diagnosis
among statin-users in comparison to non-users (odds ratio [OR]: 1.13; 95% confidence
interval [95%-CI]: 1.06–1.20) (Table 2). The total number of patients diagnosed with
influenza during the follow-up period among statin-users was 145 (1.1%) and among non-
users was 307 (0.9%). The adjusted OR for influenza infection was similar among statin-
users and non-users (OR: 1.06, 95%-CI: 0.80–1.39).
The total number of patients diagnosed with fungal infections during the follow-up period
among statin-users was 3,171 (24.4%) and among non-users was 5,667 (17.6%). The
adjusted OR for fungal infection was similar among statin-users and non-users (OR: 0.97,
95%-CI: 0.91–1.04).
Table 3 depicts the time-to-event analysis for the occurrence of the first infection. There
were no statistically significant differences in the hazard ratio of infectious disease outcome
groups.
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The results of this retrospective study suggest that statin use is associated with higher
incidence of common infections, but not influenza or fungal infections. Previous studies that
addressed the effect of statin therapy on infections have focused on two general aspects:
investigating the association of statins with the incidence of infections (that is, the effect of
statins in preventing infections) and the association of statins with severity of infections,
such as mortality. This study did not evaluate the effect of statins on the severity of infection
or mortality; rather it focused on the association of statin therapy and the incidence of
infections.
Several observational studies have investigated the role of statins in the prevention of
infection.16, 50–53 These studies varied by population size, with most including fewer than
5,000 patients. Most studies noted that statin use was associated with decreased risk of
infection. Hackam et al analyzed data from a large population-based cohort study in Ontario,
Canada from 1997 to 2002.11 Propensity score-match subgroups were created in the
identified 141,487 patients older than 65 years who had been hospitalized for an acute
coronary syndrome, ischemic stroke, or revascularization. The matched cohort included
69,168 patients (34,584 statin-users and 34,584 non-users). After adjustments for
demographic characteristics, sepsis risk factors, comorbidities, and health care use, the risk
of sepsis was lower in statin-users (hazard ratio [HR]: 0.81; 95% CI: 0.72–0.90).11
However, not all studies support a protective effect of statins from infection. One case-
control study (1,125 validated cases of pneumonia and 2,235 matched controls) found no
association between statin use and risk of infection after adjusting for functional and
cognitive status.51 Another large population-based cohort study used a propensity score-
based method to control for differences between statin-users and non-users in the United
Kingdom. Statin-users (n=129,288) were compared with a matched sample of 600,241
people who did not receive statins, with a median follow-up period of 4.4 years. The
investigators noted that statin use was not associated with an effect on a wide range of
outcomes, including infections.54
Two meta-analyses have concluded that statins appear to prevent infections;25, 26 however,
in a recent meta-analysis of large randomized controlled trials that investigated the effects of
statins on cardiovascular mortality, statins were not found to be beneficial in preventing
infection.55
Studies that investigated the effects of statins on the severity of infection, whether the
development of severe infection or infection-related mortality, have also yielded mixed
results.11–16, 19, 22 Several studies found that prior use of statins was associated with less
mortality in sepsis or pneumonia.8, 9, 14, 15, 56, 57 Other studies found no difference in
mortality in statin-users versus non-users,20, 21 or worse outcomes.23
The present study also investigated the effect of statins on the development of fungal
infections, for which there is a paucity of published literature compared to bacterial
infections. Forrest et al investigated the effect of statins on mortality in ICU patients with
candidemia and found a beneficial effect.58 Another retrospective cohort study on diabetic
patients undergoing gastrointestinal surgery found a decreased incidence of candidal
infections among statin-users;59 however, a small case-control study evaluating the effect of
statins on the incidence of invasive fungal infections (including zygomycosis, aspergillosis
and candidal invasive infections) found no difference between statin-users and non-users.60
Fewer studies have been performed to investigate the effect of statins on influenza. A
retrospective case-control study on pre-hospital statin use and its effect on the severity of
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inpatient influenza infection found no significant correlation.61 Vandermeer et al performed
a retrospective cohort of patients hospitalized with laboratory-confirmed influenza
infection.62 Pre-hospital or inpatient statin use was correlated with decreased mortality in
patients with influenza. The present study did not evaluate the effect of statins on the
severity of influenza, but on the incidence of influenza. The study revealed no difference in
the incidence of influenza among statin-users versus non-users; however, these results
should be cautiously interpreted due to the small proportion of patients with influenza
infection (approximately 1%).
The controversy regarding the cause of these conflicting results regarding the effect of
statins on infection prevention includes the choice of outcome measures utilized and the
method of adjusting for baseline confounders.63 One caveat in population-based cohort
studies is the “healthy-user bias”. Studies have shown that statin use may be a surrogate
marker for a more “health-conscious patient” (healthy-user bias). In a prospective cohort
study of patients who initiated statin therapy for primary cardiovascular prevention, statin-
adherent patients were less likely than non-adherent patients to have motor vehicle accidents
and workplace accidents, after adjusting for potential confounders.27 Additionally, since
adherence to statin therapy was associated with the use of preventive health services,28 statin
use may be a surrogate marker for a better health care system, better access to care, or
presence of medical insurance. Additionally, publication bias may play a role in
overestimating the benefits of statins. In a systematic review and meta-analysis, seven
cohort studies that addressed infection prevention in association with statin use were
identified.26 The pooled effect estimate showed a lower incidence of infection associated
with statin use (OR: 0.57; 95% CI: 0.43–0.75).26 However, the authors noted that the funnel
plot summary of identified studies is suggestive of publication bias; hence, the treatment
effect may be overestimated.
This study contributes to the current literature in several ways. The study population
represents a more homogenous sample of patients in regard to health care system
accessibility, affordability, and utilization, which, collectively, minimize biases that may
have been encountered in prior investigations. However, equal access to care does not
equate to equal utilization of care. This study also included both inpatient and outpatient
medical records. Analysis included adjustments for several potential confounders such as
age, gender, total Charlson comorbidity score, utilization of specific classes of medications,
and health care utilization (number of inpatient admissions and outpatient visits). Health
care utilization is an important confounder that may result in ascertainment bias. Frequent
health care utilization may result in more disease diagnoses, and hence, a falsely increased
incidence of diseases among its population.
There are several limitations to the study. Due to the retrospective study design, there are
significant differences in baseline characteristics between the two comparison groups.
Despite adjusting for several potential baseline confounders, there may be other differences
between the groups that were not accounted for. Other factors, such as severity of illness or
other comorbidities may have accounted for differences in outcome between statin-users and
non-users. Furthermore, despite the large sample size, some diagnoses had small total
numbers of encounters, such as influenza. The lack of effect for these secondary outcomes
may be explained by insufficient power to detect a difference. Another limitation for our
study is that we used a convenience sample of ICD-9 diagnoses that encompass the most
commonly encountered infections in clinical practice. Ideally, we should have included all
possible infections, except for the time and cost. Additionally, the use of administrative data
to identify some infections such as pneumonia and influenza may not be accurate.64, 65 The
use of pharmacy data and billing claims to account for medication use assumes that patients
are actually taking their medications and not simply filling their prescriptions. Such an
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assumption cannot be ascertained, though, it may be argued that the long duration of use
(approximately 95% of our statin-users dispensed a statin for more than a year) can be
considered as a surrogate marker for actual use.
In conclusion, statin use in this study was not associated with a protective role on incidence
of infections. Further randomized studies or large registries are required to more definitively
ascertain the relationship between statin use and infection.
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Table 1
Baseline characteristics of statin-users and non-users
Statin-users (n = 12,981) Non-users (n = 32,266)
Age (years), mean ± SD 59.3 ± 11.5 44.4 ± 10.7 < 0.0001
Female gender, n (%) 5,342 (41.2) 18,125 (54.2) < 0.0001
Charlson Comorbidity Score variables:
 Acute myocardial infarction, n (%) 711 (5.5) 112 (0.3) < 0.0001
 Congestive heart failure, n (%) 650 (5) 137 (0.4) < 0.0001
 Peripheral vascular disease, n (%) 767 (5.9) 169 (0.5) < 0.0001
 Cerebrovascular disease, n (%) 478 (3.7) 205 (0.6) < 0.0001
 Dementia, n (%) 41 (0.3) 33 (0.1) < 0.0001
 Chronic obstructive pulmonary diseases, n (%) 1,938 (14.9) 2,398 (7.4) < 0.0001
 Rheumatologic diseases, n (%) 277 (2.1) 456 (1.4) < 0.0001
 Peptic ulcer disease, n (%) 195 (1.5) 249 (0.8) < 0.0001
 Mild liver disease, n (%) 47 (0.4) 113 (0.4) 0.9
 Diabetes mellitus, n (%) 4,188 (32.3) 826 (2.6) < 0.0001
 Diabetes mellitus with complications, n (%) 1,577 (12.1) 171 (0.5) < 0.0001
 Hemiplegia/paraplegia, n (%) 45 (0.3) 25 (0.1) < 0.0001
 Renal disease, n (%) 430 (3.3) 110 (0.3) < 0.0001
 Malignancy, n (%) 918 (7.1) 1,042 (3.2) < 0.0001
 Liver disease (moderate/severe), n (%) 7 (0.1) 39 (0.1) 0.05
 Metastatic neoplasm, n (%) 43 (0.3) 95 (0.3) 0.5
 Human immunodeficiency virus, n (%) 13 (0.1) 39 (0.1) 0.6
Charlson Comorbidity Total Score, mean ± SD 1.2 ± 1.6 0.26 ± 0.8 < 0.0001
Alcohol abuse/dependence, n (%) 128 (1) 234 (0.7) .006
Tobacco use, n (%) 1,215 (9.4) 1,891 (5.9) < 0.0001
HDL-C in baseline period, mean ± SD 52.3 ± 14.4 58.3 ± 17.8 < 0.0001
HDL-C in follow-up period, mean ± SD 51 ± 13.5 57 ± 16.5 < 0.0001
LDL-C in baseline period, mean ± SD 105.9 ± 33.9 111.1 ± 27.9 < 0.0001
LDL-C in follow-up period, mean ± SD 98.7 ± 31.5 112.6 ± 27.3 < 0.0001
Number of outpatient visits during baseline period, mean ± SD 39.8 ± 44.3 22.7 ± 31.6 < 0.0001
Number of inpatient admissions during baseline period, mean ± SD 0.4 ± 1 0.18 ± 0.6 < 0.0001
Medications:
 Beta-blocker, n (%) 3,610 (27.8) 2,062 (6.4) < 0.0001
 Diuretic, n (%) 4,764 (36.7) 3,249 (10.1) < 0.0001
 Calcium channel blocker, n (%) 3,214 (24.8) 1,521 (4.7) < 0.0001
 ACEI/ARB, n (%) 7,504 (57.8) 3,303 (10.2) < 0.0001
 Oral hypoglycemic, n (%) 2,707 (20.9) 376 (1.2) < 0.0001
 Aspirin, n (%) 6,839 (52.7) 2,513 (7.8) < 0.0001
 Systemic corticosteroid, n (%) 515 (4) 1,360 (4.2) 0.24
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ACEI/ARBs= Angiotensin converting enzyme inhibitors/angiotensin-receptor blockers &; HDL=High-density lipoprotein in mg/dL; LDL= Low-
density lipoprotein in mg/dL; SD= standard deviation
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Table 2
Comparison of infectious diseases outcome between statin-users and non-users
Infection Statin-Users (n=12,981) Non-Users (n=32,266) Adjusted OR (95% CI) *
n (%) n (%)
Common infections group 8,939 (68.9) 19,323 (59.9) 1.13 (1.06–1.19)
Influenza 145 (1.1) 307 (0.9) 1.06 (0.80–1.39)
Fungal infections 3,171 (24.4) 5,667 (17.6) 0.97 (0.91–1.04)
*
Logistic regression analysis; covariates were patient age, patient gender, total Charlson Comorbidity Score, tobacco use, alcohol use/abuse,
number of inpatient admissions in the baseline period, number of outpatient admissions in the baseline period, and use of the following
medications: beta-blockers, diuretics, calcium-channel blockers, ACE inhibitors/ARBs, oral hypoglycemics, aspirin, and steroids.
OR=odds ratio, CI=confidence interval
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Table 3
Comparison of time-to-first infection in statin-users and non-users
Infection, mean ± SD (days) Statin-Users (n = 12,981) Non-Users (n = 32,266) Adjusted HR (95% CI)
Common infections group 614 ± 409 637 ± 412 0.99 (0.95–1.02)
Influenza 745 ± 470 813 ± 463 1.10 (0.83–1.46)
Fungal infections 771 ± 434 727 ± 428 0.99 (0.93–1.05)
*
Proportional Hazards Regression; Time in days; covariates were patient age, patient gender, total Charlson Comorbidity Score, tobacco use,
alcohol use/abuse, number of inpatient admissions in the baseline period, number of outpatient admissions in the baseline period, and use of the
following medications: beta-blockers, diuretics, calcium-channel blockers, ACE inhibitors, oral hypoglycemics, aspirin, and steroids.
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